Japanese Dermatological Association Guidelines: Outlines of Guidelines for Cutaneous Squamous Cell Carcinoma 2020.
actinic keratosis
bowen disease
guidline
solar keratosis
squamous cell carcinoma
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
18
03
2021
received:
08
03
2021
accepted:
22
03
2021
pubmed:
9
5
2021
medline:
6
7
2021
entrez:
8
5
2021
Statut:
ppublish
Résumé
In consideration of the development of treatment options for squamous cell carcinoma (SCC), the Japanese Skin Cancer Society issued the first guidelines of SCC in 2007 and revised them in 2015. Here, we report the English version of the 2020 edition of the Japanese SCC guidelines. The first half of this article is an overview of SCC including actinic keratosis and Bowen's disease, and the second half discusses three clinical questions: (i) treatment of actinic keratosis; (ii) determination of the resection margin of the primary lesion; and (iii) treatment of radically incurable cases, as contemporary problems encountered in treating SCC. In these evaluations, all processes were implemented according to the Grading of Recommendations, Assessment, Development, Evaluation system. Also, items of recommendation concerning each clinical question were determined by a multidisciplinary expert panel consisting of dermatologists, plastic/reconstructive surgeons, radiologists, and oncologists through a comprehensive literature search and systematic reviews.
Identifiants
pubmed: 33963604
doi: 10.1111/1346-8138.15889
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e288-e311Informations de copyright
© 2021 Japanese Dermatological Association.
Références
Sakamoto A. Squamous cell carcinoma. In: Kitagawa M, Niki T, editors. Hyoujunn Byourigaku, 5th edn, Tokyo: Igakushoin; 2015. p. 255 [In Japanese].
Squamous cell carcinoma. In: The Japanese skin cancer society, editors, General rules for clinical and pathological studies on malignant neoplasms of the skin, 2nd edn. Tokyo: Kanehara syuppan; 2010. p. 40-6 [In Japanese].
Heppt MV, Schlager G, Berking C. Epithelial precancerous lesions. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., Fitzpatrick’s dermatology general medicine, 9th edn. New York: McGraw-Hill; 2019. p. 1857-83.
Mihm MC Jr, et al. Actinic keratosis. In: Elder DE, et al., editors. WHO classification of skin tumours. 4th ed. Lyon: International Agency for Research on Cancer; 2018. p. 51-2.
Ishihara K, Ikeda S, Mori S. The diagnosis and treatment guidelines for malignant skin tumors and the result of nationwide questionnaire. Skin Cancer. 1994;9:7-12 [In Japanese].
Ishihara K. Epidemiology of malignant skin tumors in Japan. Skin Cancer. 1997;12:18-25 [In Japanese].
Takenouchi T, Takatsuka S. Statistics of skin cancer in 1973-2010. Journal of Niigata Cancer Center Hospital. 2011;50:136-9 [In Japanese].
Ishihara K. Past statistics and prognostic factors for malignant skin tumors. Skin Cancer. 2007;22:209-16 [In Japanese].
Ishii Y, Sakaino M, Watanabe S, Kubota N, Onizawa S, Maruyama H, et al. A nationwide survey of squamous cell carcinoma and Bowen’s disease in Japan. Skin Cancer. 2013;28:195-204 [In Japanese].
Fujisawa Y. The latest epidemiological data on skin tumors. Maruho Dermatology Seminar, 2012. http://medical.radionikkei.jp/maruho_hifuka_pdf/maruho_hifuka-121206.p [In Japanese]
Ishihara K. Ultraviolet and skin cancer from the point of statistical surveys, and skin damage due to ultraviolet and its countermeasures. Biotherapy. 2005;19:411-6 [In Japanese].
Ichihashi M. Photoaging. Rinsho Derma (Tokyo). 2001;43:1305-12 [In Japanese].
NICE Guidance Skin cancer prevention. https://www.nice.org.uk/guidance/ph32
Work Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olenecki T, Rodgers P. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:560-78.
Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol. 2010;146:279-82.
Koh HK, Geller AC, Miller DR, Grossbart TA, Lew RA. Prevention and early detection strategies for melanoma and skin cancer. Current status. Arch Dermatol. 1996;132:436-43.
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151:1081-6.
Mansouri B, Housewright CD. The treatment of actinic keratoses-the rule rather than the exception. JAMA Dermatol. 2017;153:1200.
Baum CL, Wright AC, Martinez JC, Arpey CJ, Brewer JD, Roenigk RK, et al. A new evidence-based risk stratification system for cutaneous squamous cell carcinoma into low, intermediate, and high risk groups with implications for management. J Am Acad Dermatol. 2018;78:141-7.
Gloster HM Jr, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006;55:741-60; quiz 761-64.
Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55:490-500.
Saida T. Diagnosis and management of cutaneous squamous cell carcinoma. Skin Cancer. 1994;9:69-72 [In Japanese].
Friedberg EC, et al. DNA repair and mutagenesis. Washington, DC: ASM Press; 2005.
Lin CT, Lin WH, Lee KD. Tzeng PY DNA mismatch repair as an effector for promoting phorbol ester-induced apoptotic DNA damage and cell killing: implications in tumor promotion. Int J Cancer. 2006;119:1776-84.
Cleaver JE. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer. 2005;5:564-73.
Bangash HK, Colegio OR. Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients. Curr Treat Options Oncol. 2012;13:354-76.
Kimura K, Terui T. Malignant neoplasms of the skin - Squamous cell carcinoma, clinical diagnosis. Nippon Rinsho. 2013;71:479-82 [In Japanese].
Elder DE, Massi D, Scolyer RA, et al., editors. Squamous cell carcinoma. In: WHO Classification of Skin Tumours (WHO Classification of Tumours: International Agency for Research on Cancer). Lyon: International Agency for Research on Cancer; 2018. p. 35-6.
Habif TP. Premalignant and malignant nonmelanoma skin tumors. In: Habif TP, editor. Clinical dermatology, 6th edn. Edinburgh, UK: Elsevier; 2015. p. 830-4.
Elder DE, Massi D, Scolyer RA, et al. editors. Premalignant keratosis. In: WHO Classification of Skin Tumours (WHO Classification of Tumours: International Agency for Research on Cancer). Lyon: International Agency for Research on Cancer; 2018. p. 51-3.
Habif TP. Premalignant and Malignant Nonmelanoma Skin Tumors. In: Habif TP, editor. Clinical dermatology, 6th edn. Edinburgh, UK: Elsevier; 2015. p. 819-28.
Elder DE, Massi D, Scolyer RA, et al. editors. Squamous cell carcinoma in situ (Bowen disease). In: WHO Classification of Skin Tumours (Who Classification of Tumours: International Agency for Research on Cancer). Lyon: International Agency for Research on Cancer; 2018. p. 46-7.
Murphy GF, Beer TW, Cerio R, Kao GF, Nagore E, Pulitzer MP. Squamous cell carcinoma. In: Elder DE, Massi D, Scolyer RA, Willemze R, editors. WHO classification of Skin Tumours, 4th edn. Lyon: International Agency for Research on Cancer; 2018. p. 35-45.
Cassarino DS, DeRienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification, part one. J Cutan Pathol. 2006;33:191-206.
Fukumoto D, Ansai S, Fukumoto M, Kubo Y, Arase S, Nakanishi H. A clinicopathological study of primary cutaneous squamous cell carcinoma: relationship between a new clinicopathological classification and prognosis. Jpn J Dermatol. 2011;121:2247-56.
Ackerman AB, Reddy VB, Soyer HP. Neoplasms with follicular differentiation. New York: Ardor Scribendi Publishers; 2001.
Ansai S, Fukumoto T, Kimura T. A ckinicopathological study of primary cutaneous squamous cell carcinoma. Jpn J Dermatol. 2008;118:29-36.
Nappi O, Pettinato G, Wick MR. Adenoid (acantholytic) squamous cell carcinoma of the skin. J Cutan Pathol. 1989;16:114-21.
Griffin JR, Wriston CC, Peters MS, Lehman JS. Decreased expression of intercellular adhesion molecules in acantholytic squamous cell carcinoma compared with invasive well-differentiated squamous cell carcinoma of the skin. Am J Clin Pathol. 2013;139:442-7.
Pyne JH, Myint E, Barr EM, Clark SP, David M, Na R. Acantholytic invasive squamous cell carcinoma: tumor diameter, invasion depth, grade of differentiation, surgical margins, perineural invasion, recurrence and death rate. J Cutan Pathol. 2017;44:320-7.
Cassarino DS, DeRienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification, part two. J Cutan Pathol. 2006;33:261-79.
Ansai S, Takeichi H, Arase S, Kawana S, Kimura T. Sebaceous carcinoma: an immunohistochemical reappraisal. Am J Dermatopathol. 2011;33:579-87.
Barzilai G, Greenberg E, Cohen-Kerem R, Doweck I. Pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg. 2005;132:852-6.
NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesⓇ) Squamous cell Skin Cancer Version 2. 2018-October 5, 2017. https://oncolife.com.ua/doc/nccn/Squamous_Cell_Skin_Cancer.pdf
Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51:1989-2007.
Nemzek WR, Hecht S, Gandour-Edwards R, Donald P, McKennan K. Peri-neural spread of head and neck tumors: how accurate is MR imaging? Am J Neuroradiol. 1998;19:701-6.
Sharma A, Jaiswal AA, Umredkar G, Barle R, Sharma N, Banerjee PK, et al. Lymph node central necrosis on the computed tomography as the predictor of the extra capsular spread in metastatic head and neck squamous cell carcinoma. Indian J Otolaryngol Head Neck Surg. 2017;69:323-32.
Hirshoren N, Olayos E, Herschtal A, Ravi Kumar AS. Gyorki DE1, preoperative positron emission tomography for node-positive head and neck cutaneous squamous cell carcinoma. Otolaryngol Head Neck Surg. 2017;158:122-6.
Cho SB, Chung WG, Yun M, Lee JD, Lee MG, Chung KY. Fluorodeoxyglucose positron emission tomography in cutaneous squamous cell carcinoma: retrospective analysis of 12 patients. Dermatol Surg. 2005;31:442-47.
Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys. 2001;49:1061-9.
Weedon D, et al. Verrucous squamous cell carcinoma. In: LeBoit PE, et al. editors. World Health Organizati classification of tumours, pathology & genetics, skin tumours. Lyon: IARC Press; 2006. p. 22-3.
Murphy GF, et al. Verrucous squamous cell carcinoma. In: Elder DE, et al. editors. WHO classification of skin tumours, 4th edn. WHO; 2018. p. 41-2.
Headington JT. Verrucous carcinoma. Cutis. 1978;21:207-11.
Kirkham N, Aljefri K. Verrucous carcinoma. In: Elder DE, et al. editors. Lever’s histopathology of the skin, 11th edn. Philadelphia: Wolters Kluwer, 2015. p. 1004-5.
Boyd AS. Verrucous carcinoma. In: Barnhill RL, et al. editors. Dermatopathology, 3rd edn. New York: McGrawHill; 2010. p. 596-8.
Habif TP. Benign skin tumors. In: Baxter S, editor. Clinical dermatology, 3rd edn. St. Louis: Mosby-year book; 1996. p. 638-9.
Nagano T. Dermatology seminarium - Keratoacanthoma. Jpn J Dermatol. 2009;199:1049-63 [In Japanese].
Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15:332-42.
Weedon D, Haneke E, Martinka M, et al. Acanthomas. In: LeBoit PE, Burg G, Weedon D, Sarasin A, editors. World health organization classification of tumours. Lyon: IARC Press; 2006. p. 39-47.
Ansai S, Kimura T. Keratoacanthoma -Current topics-. Practical. Dermatology. 2010;32:600-6 [In Japanese].
Takai T, Misago N, Murata Y. Natural course of keratoacanthoma and related lesions after partial biopsy: clinical analysis of 66 lesions. J Dermatol. 2015;42:353-62.
Takai T. Advances in histopathological diagnosis of keratoacanthoma. J Dermatol. 2017;44:304-14.
Tsuchida T, Koga H, Uhara H, Japanese Skin Cancer Society. Evidence-based practice guideline for malignant skin tumors, 2nt edn. Jpn J Dermatol. 2015;125: 5-75 [In Japanese].
Ansai S, Takayama R, Kimura T, , Kawana S. Ber-EP4 is a useful marker for follicular germinative cell differentiation of cutaneous epithelial neoplasms. J Dermatol. 2012;39:688-92.
Goto K, Takai T, Fukumoto T, Anan T, Kimura T, Ansai SI, et al. CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma. J Cutan Pathol. 2016;43:219-26.
Chen ELA, Srivastava D, Nijhawan RI. Mohs micrographic surgery: development, technique, and applications in cutaneous malignancies. Semin Plast Surg. 2018;32:60-8.
Rowe DE, Caroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol. 1992;26:976-90.
van Lee CB, Roorda BM, Wakkee M, Voorham Q, Mooyaart AL, de Vijlder HC, et al. Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study. Br J Dermatol. 2018;181:338-43 [Epub ahead of print].
Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I, Experience over 10 years. J Am Acad Dermatol. 2005;53:253-60.
Fukushima S, Masuguchi S, Igata T, Harada M, Aoi J, Miyashita A, et al. Evaluation of sentinel node biopsy for cutaneous squamous cell carcinoma. J Dermatol. 2014;41:539-41.
Tejera-Vaquerizo A, García-Doval I, Llombart B, Cañueto J, Martorell-Calatayud A, Descalzo-Gallego MA, et al. Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma. J Dermatol. 2018;45:781-90.
Renzi C, Caggiati A, Mannooranparampil TJ, Passarelli F, Tartaglione G, Pennasilico GM, et al. Sentinel lymph node biopsy for high risk cutaneous squamouscell carcinoma: case series and review of the literature. Eur J Surg Oncol. 2006;25:364-9.
Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg. 2006;32:1309-21.
Maruyama H, Tanaka R, Fujisawa Y, Nakamura Y, Ito S, Fujimoto M. Availability of sentinel lymph node biopsy for cutaneous squamous cell carcinoma. J Dermatol. 2017;44:431-7.
Takahashi A, Imafuku S, Nakayama J, Nakaura J, Ito K, Shibayama Y. Sentinel node biopsy for high-risk cutaneous squamous cell carcinoma. Eur J Surg Oncol. 2014;40:1256-62.
Ishihara K. Statistics and prognostic factors for malignant skin tumors in Japan: malignant melanoma. Skin Cancer. 2005;20:234-48 [In Japanese].
North JH Jr, Spellman JE, Driscoll D, , Velez A, Kraybill WG, Petrelli NJ. Advanced cutaneous squamous cell carcinoma of the trunk and extremity: Analysis of prognostic factors. J Surg Oncol. 1997;64:212-7.
Xiao Y, Yuan S, Liu F, Liu B, Zhu J, He W, et al. Comparison between wait-and-see policy and elective neck dissection in clinically N0 cutaneous squamous cell carcinoma of head and neck. Medicine. 2018;97:e10782.
Tintle SM, Levin LS. The reconstructive microsurgery ladder in orthopaedics. Injury. 2013;44:376-85.
Tsuchida Y. Treatment of traumatic skin defects. Rinsho Seikei Geka. 2009;44:783-9 [In Japanese].
Gottlieb LJ, Krieger LM. From the reconstructive ladder to the reconstructive elevator. Plast Reconstr Surg. 1994;93:1503-4.
Badashi I, Shauly O, Lui CG, et al. Nonmelanoma facial skin cancer: a review of diagnostic strategies, surgical treatment, and reconstructive technique. Clin Med Insights Ear Nose Throat. 2019;12:1179550619865278. https://doi.org/10.1177/1179550619865278
Ogata D. The reconstruction technique for the skin defects after excision of skin/soft tissue malignancies. Skin Cancer. 2018;33:138-44 [In Japanese].
Lee KS, Kim JO, Kim NG, et al. A comparison of the local flap and skin graft by location of facial reconstruction after resetion of facial skin cancer. Arch Craniofac Surg. 2017;18:255-60.
Kimura C, Sakurai K, Ohashi K, Sugino M. Local skin flap versus skin graft after resection of malignant skin tumors of the nose. Skin Cancer. 2009;24:416-22 [In Japanese].
Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344:975-83.
Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys. 2004;60:406-11.
Strom TJ, Caudell JJ, Harrison LB. Management of BCC and SCC of the head and neck. Cancer Control. 2016;23:220-6.
Tanvetyanon T, Padha T, McCaffrey J, , Kish JA, Deconti RC, Trotti A, et al. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015;37:840-5.
Nottage MK, Lin C, Hughes BGM, et al. Prospective study of definitive chemoraiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck. 2017;39:679-68.
Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, Kenny LM, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial. J Clin Oncol. 2018;36:1275-83.
Jarkowski A 3rd, Hare R, Loud P, , Skitzki JJ, Kane JM, May KS, et al. Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): the roswell park experience and a review of the literature. Am J Clin oncol. 2016;39:545-8.
Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66:1692-6.
Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29:3419-26.
Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Eng J Med. 2018;379:341-51.
Japanese Dermatological Association and the Japanese Skin Cancer Society, editors. Evidence-based practice guideline for malignant skin tumors, 2nd edn. Tokyo: Kanehara Syuppan; 2015. p. 55-9.[In Japanese]
Ishikawa M. Management of locally advanced skin cancer. Nippon Rinsho. 2013;71:565-7 [In Japanese].
Umebayashi Y. Radiotherapy, chemotherapy and topical therapy for squamous cell carcinoma. In: Yamazaki N, et al. editors. Hihukarinnsyoasetto17 Malignant tumor of the skin. Tokyo: Nakayama syoten; 2014. p. 236-40.[In Japanese]
Ishihara K. The result and explanation of nationwide questionnaire. Skin Cancer. 1994;9:72-7 [In Japanese].
Omata W, Oashi K, Namikawa K, Tsutsumida A, Yamazaki N. A statistical analysis of squamous cell carcinoma at the Department of Dermatologic Oncology, National Cancer Center Hospital in Japan. Skin Cancer. 2013;28:154-9 [In Japanese].
Ito Y, Wada T, Asano K, Takahashi H, Oashi K, Namikawa K, et al. A statistical analysis of squamous cell carcinoma at the Department of Dermatologic Oncology, National Cancer Center Hospital in Japan. Jpn J Dermatol. 2002;112:961-7 [In Japanese].
Souza J, Clark J. Management of the neck in metastatic cutaneous squamous cell carcinoma of the head and neck. Curr Opin Otolaryngol Head Neck Surg. 2011;19:99-105.
Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35:574-85.
Saida T. Diagnosis and treatment of actinic keratosis. Skin Cancer. 2010;25:214-31 [In Japanese].
Habif TP. Premalignant and Malignant Nonmelanoma Skin Tumors. In: Habif TP, editor. Clinical dermatology, 6th edn. Edinburgh, UK: Elsevier; 2015. p. 819-28.
Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2017;177:350-8.
Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. l: Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009;115:2523-30.
Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratosis to squamous cell carcinoma. Lancet. 1988;1:795-7.
Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329:1147-51.
Darlington S, Williams G, Neale R, Frost C, Green A. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol. 2003;139:451-5.
Nagano T, Ueda M, Suzuki T, Naruse K, Nakamura T, Taguchi M, et al. Skin cancer screening in Okinawa, Japan. J Dermatol Sci. 1999;19:161-5.
Neagu TP, Ţigliş M, Botezatu D, Enache V, Cobilinschi CO, Vâlcea-Precup MS, et al. Clinical, histological and therapeutic features of Bowen’s disease. Rom J Morphol Embryol. 2017;58:33-40.
Morton CA, Birnie AJ, Eedy DJ. British Association of Dermatologists’ guidelines for the management of squamous cell carcinoma in situ (Bowen’s disease) 2014. Br J Dermatol. 2014;170:245-60.
Hirose R, Tomimura S, Takeishi E, Yokoyama Y. A study of positive lateral margin casesin actinic keratoses. Skin Cancer. 2010;25:85-9 [In Japanese].
Hansen JP, Drake AL. Walling HW Bowen’s Disease: a four-year retrospective review of epidemiology and treatment at a university center. Dermatol Surg. 2008;34:878-83.
Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Cutaneous squamous carcinoma in situ (Bowen’s disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol. 2005;52:997-1002.
Holt PJ. Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgery. Br J Dermatol. 1988;119:231-40.
Morton CA, Whitehurst C, Moseley H, McColl JH, Moore JV, Mackie RM. Comparisonof photodynamic therapy with cryotherapy in the treatment of Bowen’s disease. Br J Dermatol. 1996;135:766-71.
Morton C, Horn M, Leman J, Tack B, Bedane C, Tjioe M, et al. Comparison of topicalmethyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol. 2006;142:729-35.
Ahmed I, Berth-Jones J, Charles-Holmes S, O’Callaghan CJ, Ilchyshyn A. Comparison of cryotherapy with curettage in the treatment of Bowen’s disease: a prospective study. Br J Dermatol. 2000;143:759-66.
Fayter D, Corbett M, Heirs M, Fox D, Eastwood A. C A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess. 2010;14:1-288.
Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br J Dermatol. 2003;148:539-43.
Cai H, Wang YX, Zheng JC, Sun P, Yang ZY, Li YL, et al. Photodynamic therapy in combination with CO2 laser for the treatment of Bowen’s disease. Lasers Med Sci. 2015;30:1505-10.
Thestrup-Pedersen K, Ravnborg L, Reymann F. Morbus Bowen. A description of the disease in 617 patients. Acta Derm Venereol. 1988;68:236-9.
Bargman H, Hochman J. Topical treatment of Bowen’s disease with 5-Fluorouracil. J Cutan Med Surg. 2003;7:101-5.
Sturm HM. Bowen’s disease and 5-fluorouracil. J Am Acad Dermatol. 1979;1:513-22.
Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, et al. Imiquimod 5%cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54:1025-32.
Morton C, Horn M, Leman J, Tack B, Bedane C, Tjioe M, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ. Archiv Dermatol. 2006;142:729-35.
Walker JL, Siegel JA, Sachar M, Qureshi AA, Chen SC, Swetter SM, et al. 5-Fluorouracil for actinic keratosis treatment and chemoprevention: a randomized controlled trial. J invest dermatol. 2017;137:1367-70.
Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalian H, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127:106-16.
Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat. 2003;14:99-106.
Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton PG, Zane C, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol. 2002;47:258-62.
Zane C, Facchinetti E, Rossi MT, Specchia C, Ortel B, Calzavara-Pinton P. Cryotherapy is preferable to ablative CO2 laser for the treatment of isolated actinic keratoses of the face and scalp: a randomized clinical trial. Br J Dermatol. 2014;170:1114-21.
Sotiriou E, Apalla Z, Maliamani F, Zaparas N, Panagiotidou D, Ioannides D. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol. 2009;23:1061-5.
Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up, British. J Dermatol. 2007;157:34-40.
Hantash BM, Stewart DB, Cooper ZA, Rehmus WE, Koch RJ, Swetter SM. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol. 2016;142:976-82.
Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratosis. Int J Dermatol. 2001;40:709-13.
Surjana D, Halliday GM, Martin AJ, Moloney FJ, Damian DL. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol. 2002;132:1497-500.
Newlands C, Currie R, Memon A, Whitaker S, Woolford T. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S125-S132.
Weinstein MC, Brodell RT, Bordeaux J, Honda K. The art and science of surgical margins for the dermatopathologist. Am J Dermatopathol. 2012;34:737-45.
Kauvar AN, Arpey CJ, Hruza G, Olbricht SM, Bennett R, Mahmoud BH. Consensus for Nonmelanoma Skin Cancer Treatment, Part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015;41:1214-40.
Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. 1992;27:241-8.
Motley R, Kersey P, Lawrence C. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol. 2002;146:18-25.
Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. European Dermatology Forum (EDF); European Association of Dermato-Oncology (EADO); European Organization for Research and Treatment of Cancer (EORTC): Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer. 2015;51:1989-2007
Skulsky SL, O'Sullivan B, McArdle O, Leader M, Roche M, Conlon PJ, et al. Review of high-risk features of cutaneous squamous cell carcinoma and discrepancies between the American Joint Committee on Cancer and NCCN Clinical Practice Guidelines In Oncology. Head Neck. 2017;39:578-94.
Japanese Dermatological Association and the Japanese Skin Cancer Society, eds. Evidence-based Practice Guideline for Malignant Skin Tumors, 2nd edn. Tokyo: Kanehara syuppan;2015. p. 43-62. [In Japanese]
Khan AA, Potter M, Cubitt JJ, Khoda BJ, Smith J, Wright EH, et al. Guidelines for the excision of cutaneous squamous cell cancers in the United Kingdom: the best cut is the deepest. J Plast Reconstr Aesthet Surg. 2013;66:467-71.
Schell AE, Russell MA, Park SS. Suggested excisional margins for cutaneous malignant lesions based on Mohs micrographic surgery. JAMA Facial Plast Surg. 2013;15:337-43.
Ribero S, Osella Abate S, Di Capua C, Dika E, Balagna E, Senetta R, et al. Squamocellular carcinoma of the skin: clinicopathological features predicting the involvement of the surgical margins and review of the literature. Dermatology. 2016;232:279-84.
Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153.
Batchelor RJ, Stables GI. An audit of the management of cutaneous squamous cell carcinoma according to the multiprofessional guidelines. Br J Dermatol. 2006;154:1202-3.
Umebayashi Y, Akama T, Manabe M. Most cases of cutaneous squamous cell carcinoma in Japan are classified as “high risk” according to the Japanese guideline. J Dermatol. 2012;39:812-4.
The Japanese Skin Cancer Society, ed. Evidence-based Practice Guideline for Malignant Skin Tumors, 1st edn. Kanehara syuppan;2007, p. 41-57. [In Japanese]
Fahradyan A, Howell AC, Wolfswinkel EM, Tsuha M, Sheth P, Wong AK. Updates on the management of non-melanoma skin cancer (NMSC). Healthcare. 2017;5:82.
Work Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olenecki T, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:560-78.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Squamous Cell Skin Cancer. Verssion 1.2019-Augest 31, 2018.
Veness MJ. The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities. J Med Imaging Radiat Oncol. 2008;52:278-86.
Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol. 2012;67:1235-41.
Giacchero D, Barrière J, Benezery K, Guillot B, Dutriaux C, Mortier L, et al. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma-a report of eight cases. Clin Oncol (R Coll Radiol). 2011;23:716-8.
Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257-61.
Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quéreux G, et al. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatol Treatment. 2014;25:424-7.
Dereure O, Missan H, Girard C, Costes V, Guillot B. Efficacy and tolerance of cetuximab alone or combined with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinoma: an open study of 14 patients. Dermatology. 2016;232:721-30.
Samstein RM, Ho AL, Lee NY, Barker CA. Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy. J Skin Cancer. 2014;21:2014.
Sasaki S. Radiotherapy for squamous cell carcinoma. Nippon Rinsho. 2013;71(suppl 4):517-20.
Ikegawa S, Saida T, Obayashi H, Sasaki A, Esumi H, Ikeda S, et al. Cisplatin combination chemotherapy in squamous cell carcinoma and adenoid cystic carcinoma of the skin. J Dermatol. 1989;16:227-30.
Shin DM, Glisson BS, Khuri FR, Clifford JL, Clayman G, Benner SE, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.J. Clin Oncol. 2002;20:364-70.
Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 2000;23:181-4.
Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin CancerRes. 2012;18:1435-46.
William WN Jr, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017;77:1110-3.
Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25:2047-52.